|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CASC10 |
Gene summary for CASC10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CASC10 | Gene ID | 399726 |
| Gene name | MIR1915 host gene | |
| Gene Alias | C10orf114 | |
| Cytomap | 10p12.31 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 399726 | CASC10 | HCC1_Meng | Human | Liver | HCC | 1.32e-46 | 1.07e-01 | 0.0246 |
| 399726 | CASC10 | HCC1 | Human | Liver | HCC | 1.37e-03 | 9.81e-01 | 0.5336 |
| 399726 | CASC10 | HCC2 | Human | Liver | HCC | 1.84e-03 | 1.93e+00 | 0.5341 |
| 399726 | CASC10 | S014 | Human | Liver | HCC | 1.47e-05 | 2.55e-01 | 0.2254 |
| 399726 | CASC10 | S015 | Human | Liver | HCC | 5.30e-03 | 2.16e-01 | 0.2375 |
| 399726 | CASC10 | S016 | Human | Liver | HCC | 5.00e-03 | 1.66e-01 | 0.2243 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CASC10 | SNV | Missense_Mutation | c.396N>A | p.Phe132Leu | p.F132L | Q5T4H9 | protein_coding | deleterious_low_confidence(0) | benign(0.019) | TCGA-C8-A274-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| CASC10 | insertion | Frame_Shift_Ins | novel | c.306_307insAAAGT | p.Glu103LysfsTer47 | p.E103Kfs*47 | Q5T4H9 | protein_coding | TCGA-BH-A0B4-01 | Breast | breast invasive carcinoma | Male | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | ||
| CASC10 | SNV | Missense_Mutation | c.314N>T | p.Ala105Val | p.A105V | Q5T4H9 | protein_coding | tolerated_low_confidence(0.29) | benign(0.031) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| CASC10 | SNV | Missense_Mutation | c.346A>G | p.Thr116Ala | p.T116A | Q5T4H9 | protein_coding | deleterious_low_confidence(0) | benign(0.003) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CASC10 | SNV | Missense_Mutation | c.55N>T | p.Arg19Cys | p.R19C | Q5T4H9 | protein_coding | deleterious_low_confidence(0) | benign(0.134) | TCGA-B5-A11H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Hormone Therapy | megace | SD | |
| CASC10 | SNV | Missense_Mutation | c.382N>A | p.Ala128Thr | p.A128T | Q5T4H9 | protein_coding | deleterious_low_confidence(0.04) | benign(0.011) | TCGA-BK-A0C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CASC10 | SNV | Missense_Mutation | c.190N>T | p.Arg64Trp | p.R64W | Q5T4H9 | protein_coding | deleterious_low_confidence(0.03) | benign(0.001) | TCGA-D1-A101-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CASC10 | SNV | Missense_Mutation | c.166N>A | p.Pro56Thr | p.P56T | Q5T4H9 | protein_coding | tolerated_low_confidence(0.16) | benign(0.349) | TCGA-55-6642-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CASC10 | SNV | Missense_Mutation | novel | c.223N>A | p.Pro75Thr | p.P75T | Q5T4H9 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.475) | TCGA-78-8662-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| CASC10 | SNV | Missense_Mutation | novel | c.191N>T | p.Arg64Leu | p.R64L | Q5T4H9 | protein_coding | tolerated_low_confidence(0.21) | benign(0.003) | TCGA-BA-A6DA-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |